Business
UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder
UCB, a global biopharmaceutical company, today announced that the Phase 3 study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and most key secondary endpoints.3 The study is a randomized, double-blind, placebo-controlled, fixed-dose, multi-center study examining the efficacy and safety of adjunctive fenfluramine treatment in 87 individuals aged one through 35, with a CDD diagnosis and uncontrolled seizures.4
About this update from Ucb S.a.
[{"type":"list","items":[{"val":[{"type":"text","content":"Phase 3 study met primary and most key secondary clinical endpoints","length":67,"tagName":"p"}]},{"val":[{"type":"text","content":"This marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase 3 results","length":134,"tagName":"p"}]},{"val":[{"type":"text","content":"Results underscore the impact of UCB's continued investment in scientific innovation to advance new treatments for DEEs","length":128,"tagName":"p"}]},{"val":[{"type":"text","content":"CDKL5 deficiency disorder (CDD) is an ultra-rare, severe DEE with an onset in early infancy with a high unmet need, and has limited treatment options","length":149,"tagName":"p"}]},{"val":[{"type":"text","content":"CDD affects approximately 1 in 40,000 to 60,000 live births, with a median age of onset of six weeks1,2","length":103,"tagName":"p"}]},{"val":[{"type":"text","content":"UCB plans to submit for regulatory approval to bring this potential treatment option to people living with CDD as soon as possible","length":130,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":711,"olType":false},{"type":"text","content":"ATLANTA, June 27, 2025 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced that the Phase 3 study investigating the safety and efficacy of adjunctive fenfluramine in CDKL5 deficiency disorder (CDD) met its primary and most key secondary endpoints.3 The study is a randomized, double-blind, placebo-controlled, fixed-dose, multi-center study examining the efficacy and safety of adjunctive fenfluramine treatment in 87 individuals aged one through 35, with a CDD diagnosis and uncontrolled seizures.4","length":535,"tagName":"p"},{"type":"image","alt":"(PRNewsfoto/UCB, Inc.)","displaySize":"","headline":null,"caption":"(PRNewsfoto/UCB, Inc.)","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":95,"url":"https://media.zenfs.com/en/prnewswire.com/b8934a241b3f4be76014bb4ac3438a0c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/xSTzopCi9exEzsCW8PHvIg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTE2NztjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/b8934a241b3f4be76014bb4ac3438a0c","width":400,"height":95}},"href":"https://mma.prnewswire.com/media/677397/With_Tag_Logo.html","hrefExternal":true,"rel":"n...